US Pharma MarketingDefinium reports Phase 3 hit for LSD drug in severe form of depression
Definium Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing and the IRA: Tracking the government's negotiation power FDA policy and drug approvals: What’s changing…
Definium Therapeutics said its LSD candidate significantly improved depression symptoms in a Phase 3 study in major depressive disorder (MDD), with data exceeding analyst expectations.
The biotech’s drug, known as DT120, improved patients’ depression score ...
Source: Endpoints News